ADC Therapeutics SA Adjustments For Decrease Increase In Trade Account Receivable
ADC Therapeutics SA (ADCT) reported Adjustments For Decrease Increase In Trade Account Receivable of $51.79 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes › Receivables
ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable · last filed 2023-11-07
- ADC Therapeutics SA adjustments for decrease increase in trade account receivable for the quarter ending 2023-09-30 was $2.70M.
- ADC Therapeutics SA adjustments for decrease increase in trade account receivable for the quarter ending 2023-06-30 was $188.00K, a 96.81% decline year-over-year.
- ADC Therapeutics SA adjustments for decrease increase in trade account receivable for the quarter ending 2023-03-31 was $48.90M, a 1310.88% increase year-over-year.
- ADC Therapeutics SA adjustments for decrease increase in trade account receivable for the quarter ending 2022-12-31 was -$49.69M.
| Period end | Adjustments For Decrease Increase In Trade Account Receivable 3 month | Adjustments For Decrease Increase In Trade Account Receivable 6 month | Adjustments For Decrease Increase In Trade Account Receivable 9 month | Adjustments For Decrease Increase In Trade Account Receivable 12 month |
|---|---|---|---|---|
| 2023-09-30 | $2.70M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $2.89M derived: sum of 2 quarters · filed 2023-11-07 | $51.79M 6-K · filed 2023-11-07 | $2.10M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $188.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $49.09M 6-K · filed 2023-08-08 | -$600.00K derived: sum of 3 quarters · filed 2023-08-08 | -$3.02M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $48.90M 6-K · filed 2023-05-09 | -$788.00K derived: sum of 2 quarters · filed 2023-05-09 | -$3.21M derived: sum of 3 quarters · filed 2023-11-07 | $2.68M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$49.69M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$52.11M derived: sum of 2 quarters · filed 2023-11-07 | -$46.22M derived: sum of 3 quarters · filed 2023-11-07 | -$42.75M 20-F · filed 2023-03-15 |
| 2022-09-30 | -$2.42M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $3.47M derived: sum of 2 quarters · filed 2023-11-07 | $6.94M 6-K · filed 2023-11-07 | -$7.39M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $5.89M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $9.36M 6-K · filed 2023-08-08 | -$4.97M derived: sum of 3 quarters · filed 2023-08-08 | -$18.78M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $3.47M 6-K · filed 2023-05-09 | -$10.86M derived: sum of 2 quarters · filed 2023-05-09 | -$24.67M derived: sum of 3 quarters · filed 2023-05-09 | -$26.75M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$14.32M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$28.14M derived: sum of 2 quarters · filed 2023-03-15 | -$30.22M derived: sum of 3 quarters · filed 2023-03-15 | -$30.22M 20-F · filed 2023-03-15 |
| 2021-09-30 | -$13.82M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | -$15.90M derived: sum of 2 quarters · filed 2022-11-08 | -$15.90M 6-K · filed 2022-11-08 | -$15.90M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | -$2.08M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | -$2.08M 6-K · filed 2022-08-09 | -$2.08M derived: sum of 3 quarters · filed 2023-03-15 | -$2.08M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $0.00 6-K · filed 2022-05-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $0.00 derived: sum of 3 quarters · filed 2023-03-15 | $1.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $0.00 derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $0.00 derived: sum of 2 quarters · filed 2023-03-15 | $1.00K derived: sum of 3 quarters · filed 2023-03-15 | $0.00 20-F · filed 2023-03-15 |
| 2020-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $1.00K derived: sum of 2 quarters · filed 2021-11-02 | $0.00 6-K · filed 2021-11-02 | |
| 2020-06-30 | $1.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $0.00 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$1.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $192.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | $895.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |